Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,470.00
Ask: 12,474.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,482.00
Low: 12,418.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

G7 to donate 1 billion COVID-19 vaccine doses to poorer countries

Thu, 10th Jun 2021 22:30

By Kate Holton

CARBIS BAY, England, June 10 (Reuters) - British Prime
Minister Boris Johnson expects the Group of Seven to agree to
donate 1 billion COVID-19 vaccine doses to poorer countries
during its summit starting on Friday, and help innoculate the
world by the end of next year.

Just hours after U.S. President Joe Biden vowed to
supercharge the battle against the coronavirus with a donation
of 500 million Pfizer shots, Johnson said Britain would
give at least 100 million surplus vaccines to the poorest
nations.

Johnson has already called on G7 leaders to commit to
vaccinate the entire world by the end of 2022 and the group is
expected to pledge 1 billion doses during its three-day summit
in the English seaside resort of Carbis Bay.

Some campaign groups condemned the plan as a drop in the
ocean, with Oxfam estimating that nearly 4 billion people will
depend on COVAX for vaccines, the programme that distributes
COVID-19 shots to low and middle income countries.

"As a result of the success of the UK's vaccine programme we
are now in a position to share some of our surplus doses with
those who need them," Johnson will say on Friday, according to
excerpts of the announcement released by his office.

"In doing so we will take a massive step towards beating
this pandemic for good."

COVID-19 has killed around 3.9 million people and ripped
through the global economy, with infections reported in more
than 210 countries and territories since the first cases were
identified in China in December 2019.

While scientists have brought vaccines to market at
breakneck speeds - Britain has given a first dose to 77% of its
adult population and the United States 64% - they say the
pandemic will only end once all countries have been vaccinated.

With a global population nearing 8 billion and most people
needing two doses, if not booster shots to tackle variants as
well, campaigners said the commitments marked a start but world
leaders needed to go much further, and much faster.

"The G7's aim to provide 1 billion doses should be seen as
an absolute minimum, and the timeframe needs to speed up," said
Lis Wallace at anti-poverty campaign group ONE.

"We're in a race with this virus and the longer it's in the
lead the greater the risk of new, more dangerous variants
undermining global progress."

Of the 100 million British shots, 80 million will go to the
COVAX programme led by the World Health Organization (WHO) and
the rest will be shared bilaterally with countries in need.

Johnson echoed Biden in calling on his fellow leaders to
make similar pledges and for pharmaceutical companies to adopt
the Oxford-AstraZeneca model of providing vaccines at cost for
the duration of the pandemic.

Leaving poorer countries to deal with the pandemic alone
risks allowing the virus to further mutate and evade vaccines.
Charities have also said that logistical support will be needed
to help administer large numbers of vaccines in poorer
countries.

The British doses will be drawn from the stock it has
already procured for its domestic programme, and will come from
suppliers Oxford-AstraZeneca, Pfizer-BioNTech,
Janssen, Moderna and others.

(Reporting by Kate Holton; editing by Guy Faulconbridge and
Grant McCool)

More News
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.